4D Molecular Therapeutics, Inc. Common Stock FDMT
Analyst Ratings
- Consensus
- Buy — 6 Buy · 0 Hold · 0 Sell (6 analysts)
- Avg. Price Target
- $31.33 (+109.3% upside)
Key Stats
- Today's Range
- $14.33 – $15.00
- 50-Day Range
- $9.39 – $16.93
- 52-Week Range
- $4.99 – $16.93
- Volume
- 421K shs
- Average Volume
- 936K shs
- Market Cap
- $827.01 million
- P/E Ratio
- —
- Dividend Yield
- —
Valuation
- P/E Ratio
- —
- Price / Book
- 2.03
- Price / Sales
- 8.99
Short Interest
- Short Interest
- 0.41%
- Days to Cover
- 1.00
Financials (TTM)
- Revenue
- $92.01 million
- Net Income
- $-179,175,000
- Net Margin
- -194.74%
- Return on Equity
- -43.95%
- Debt-to-Equity
- —
About 4D Molecular Therapeutics, Inc. Common Stock
4D Molecular Therapeutics Inc is biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients. Companies focus is on advancing 4D-150 for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME) through late-stage studies. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-710 and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector).
Related Stocks
Compare head-to-head: FDMT vs AMGN·FDMT vs MRNA·FDMT vs HALO·FDMT vs KRYS
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.